SCHEMBL1721178

SCHEMBL1721178

CC(C)(C)OC(=O)N1CC(OCCC(=O)O)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.48
PRMT5 O14744 1/20 0.41
WDR77 Q9BQA1 1/20 0.41
USP2 O75604 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NAMPT P43490 1/20 0.38
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37
RORC P51449 1/20 0.37
HPGD P15428 1/20 0.37
USP30 Q70CQ3 1/20 0.36
GPR119 Q8TDV5 1/20 0.36
RBP4 P02753 1/20 0.36
RECQL P46063 1/20 0.35
EPHX1 P07099 1/20 0.35
KDM4E B2RXH2 1/20 0.35
PKM P14618 1/20 0.35
DDB1 Q16531 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31375710 0.88 NR1H2 (0.48) NR1H2USP2SMN1; SMN2NAMPTMEN1
SCHEMBL4035282 0.85 HPGD (0.48) PRMT5WDR77USP2SMN1; SMN2MAPT
SCHEMBL26094030 0.85 NR1H2 (0.46) NR1H2PRMT5WDR77USP2SMN1; SMN2
SCHEMBL4158576 0.84 NR1H2 (0.50) NR1H2PRMT5WDR77USP2SMN1; SMN2
SCHEMBL16419552 0.84 NR1H2 (0.50) NR1H2PRMT5WDR77USP2SMN1; SMN2
SCHEMBL2384096 0.84 NR1H2 (0.54) NR1H2PRMT5WDR77USP2SMN1; SMN2
SCHEMBL24458928 0.83 NR1H2 (0.49) NR1H2PRMT5WDR77USP2SMN1; SMN2
SCHEMBL7847383 0.83 NR1H2 (0.49) NR1H2PRMT5WDR77USP2SMN1; SMN2
SCHEMBL14714638 0.83 NR1H2 (0.49) NR1H2PRMT5WDR77USP2SMN1; SMN2
SCHEMBL30042737 0.83 NR1H2 (0.49) NR1H2PRMT5WDR77USP2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8193359-B2 G-protein coupled receptor agonists PROSIDION LIMITED (GB) 2012-06-05 US disclosed
US-8193359-B2 G-protein coupled receptor agonists PROSIDION LIMITED (GB) 2012-06-05 US disclosed
US-8193359-B2 G-protein coupled receptor agonists PROSIDION LIMITED (GB) 2012-06-05 US disclosed
EP-2406256-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS Prosidion Limited (GB) 2012-01-18 EP disclosed
WO-2010103335-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS PROSIDION LIMITED (GB) 2010-09-16 WO disclosed
US-20090099227-A1 G-Protein Coupled Receptor Agonists PROSIDION LIMITED (GB) 2009-04-16 US disclosed
US-20090099227-A1 G-Protein Coupled Receptor Agonists PROSIDION LIMITED (GB) 2009-04-16 US disclosed
US-20090099227-A1 G-Protein Coupled Receptor Agonists PROSIDION LIMITED (GB) 2009-04-16 US disclosed
EP-1838706-A1 G-PROTEIN COUPLED RECEPTOR AGONISTS Prosidion Limited (GB) 2007-10-03 EP disclosed
WO-2006067532-A1 G-PROTEIN COUPLED RECEPTOR AGONISTS PROSIDION LTD (GB) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099227-A1 G-Protein Coupled Receptor Agonists GPR119, GPR65, GPR84 NR1H2 42/4885PRMT5 2564/4885WDR77 675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.